Compare Cytokinetics Inc (CYTK) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Cytokinetics Inc trades at $81.35 (market cap $11.12B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $119.36. Which is the better fit depends on your goals.
| CYTK | QQQE | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $87.26 | $122.72 |
52-Week Low | $33.23 | $96.06 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
QQQE trades at $119.15, down 1.21% on the day, with technical indicators showing a neutral overall signal. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the Nasdaq-100, which could drive additional ETF inflows.
The equal-weight strategy offers defensive positioning during market rotations, though key financial ratios remain unavailable for analysis. Risks include market volatility and concentration in growth stocks. Analyst sentiment appears mixed with equal buy/sell signals, suggesting balanced institutional views on near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
